Strain Name:

B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J

Stock Number:

003378

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6C3F1-TgN(Prn-APP695)3Dbo TgN(Prn-PSEN1)5Dbo    (Changed: 15-DEC-04 )
Type Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Mating SystemSee Colony Maintenance under the Health & Care tab         (Female x Male)   01-MAR-06
Specieslaboratory mouse
 
Donating InvestigatorDr. David R Borchelt,   University of Florida

Description
These transgenic mice express human presenilin 1 (A246E variant) and a chimeric amyloid precursor protein (APPSwe). The mouse prion protein promoter directs expression of both transgenes. Elevated levels of the AB1-42(43) peptide is detected in brain homogenates. By nine months of age, histological examination of brain tissue reveals numerous amyloid deposits resembling those observed in the brains of patients with Alzheimer's disease (AD). The number of amyloid deposits increases dramatically between the ages of 10 and 12 months. These mice provide a useful model for studying the underlying mechanism of amyloid deposition, a process implicated in AD.

Development
Mouse pronuclei (B6C3H) were injected with an expression plasmid containing a mouse prion promoter and a cDNA encoding human presenilin 1 bearing the A246E substitution (line N-5). Another subset of mouse pronuclei (B6C3H) were injected with an expression plasmid containing a cDNA encoding a chimeric amyloid beta (A4) precursor protein, also regulated by the mouse prion promoter (line C3-3). The chimeric APP molecule was created by replacing sequences encoding the Abeta domain of the murine sequence with the cognate sequences of the human gene (mutations K595N, M596L). The two transgenic lines were subsequently mated to generate the double transgenic.

Control Information

  Control
   Noncarrier
   100010 B6C3F1/J
 
  Considerations for Choosing Controls

Related Strains

Alzheimer's Disease Models
005987   129-Achetm1Loc/J
006409   129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax
008077   129S1/Sv-Bchetm1Loc/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
014556   129S6/SvEv-Apoetm4Mae/J
006555   A.129(B6)-Tg(APPSw)40Btla/Mmjax
005708   B6.129-Apbb1tm1Quhu/J
004714   B6.129-Bace1tm1Pcw/J
004098   B6.129-Klc1tm1Gsn/J
004193   B6.129-Psen1tm1Mpm/J
003615   B6.129-Psen1tm1Shn/J
005300   B6.129-Tg(APPSw)40Btla/Mmjax
005617   B6.129P-Psen2tm1Bdes/J
002609   B6.129P2-Nos2tm1Lau/J
007685   B6.129P2-Psen1tm1Vln/J
007999   B6.129P2-Sorl1Gt(Ex255)Byg/J
008087   B6.129S1-Bchetm1Loc/J
002509   B6.129S2-Plautm1Mlg/J
005301   B6.129S2-Tg(APP)8.9Btla/J
004163   B6.129S4-Cdk5r1tm1Lht/J
010959   B6.129S4-Grk5tm1Rjl/J
010960   B6.129S4-Grk5tm2Rjl/J
002213   B6.129S4-Ngfrtm1Jae/J
006406   B6.129S4-Tg(APPSwLon)96Btla/Mmjax
006469   B6.129S4-Tg(PSEN1H163R)G9Btla/J
012564   B6.129S5-Dhcr24tm1Lex/SbpaJ
004142   B6.129S7-Aplp2tm1Dbo/J
004133   B6.129S7-Apptm1Dbo/J
007251   B6.129X1-Mapttm1Hnd/J
013040   B6.Cg-Apoetm1Unc Ins2Akita/J
005642   B6.Cg-Clutm1Jakh/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
009126   B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
008730   B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
005864   B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
007575   B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J
016197   B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J
005855   B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
004996   B6.Cg-Tg(DBH-Gal)1923Stei/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
004662   B6.Cg-Tg(PDGFB-APP)5Lms/J
006293   B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
005999   B6.Cg-Tg(SBE/TK-luc)7Twc/J
012597   B6.Cg-Tg(Thy1-COL25A1)861Yfu/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
006394   B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
008476   B6;129-Ncstntm1Sud/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
007605   B6;129P-Psen1tm1Vln/J
005618   B6;129P2-Bace2tm1Bdes/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003822   B6;129S-Psen1tm1Shn/J
012639   B6;129S4-Mapttm3(HDAC2)Jae/J
012869   B6;129S6-Apbb2tm1Her/J
006410   B6;129S6-Chattm2(cre)Lowl/J
005993   B6;129S6-Pcsk9tm1Jdh/J
008636   B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
000231   B6;C3Fe a/a-Csf1op/J
008850   B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ
004462   B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
016556   B6N.129-Ptpn5tm1Pjlo/J
018957   B6N.129S6(B6)-Chattm2(cre)Lowl/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
006554   B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
002328   C.129S2-Plautm1Mlg/J
003375   C3B6-Tg(APP695)3Dbo/Mmjax
005087   C57BL/6-Tg(Camk2a-IDE)1Selk/J
005086   C57BL/6-Tg(Camk2a-MME)3Selk/J
008833   C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J
007027   C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
010800   C57BL/6-Tg(Thy1-PTGS2)300Kand/J
010703   C57BL/6-Tg(Thy1-PTGS2)303Kand/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
007072   CByJ.129P2(B6)-Nos2tm1Lau/J
006472   D2.129(B6)-Tg(APPSw)40Btla/Mmjax
007067   D2.129P2(B6)-Apoetm1Unc/J
013719   D2.Cg-Apoetm1Unc Ins2Akita/J
003718   FVB-Tg(GadGFP)45704Swn/J
013732   FVB-Tg(NPEPPS)1Skar/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
002329   FVB.129S2-Plautm1Mlg/J
003753   FVB/N-Tg(Eno2CDK5R1)1Jdm/J
006143   FVB/N-Tg(Thy1-cre)1Vln/J
008051   NOD.129P2(B6)-Ctsbtm1Jde/RclJ
008390   STOCK Apptm1Sud/J
012640   STOCK Hdac2tm1.2Rdp/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
004779   STOCK Mapttm1(EGFP)Klt/J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
View Alzheimer's Disease Models     (109 strains)

Strains carrying   Tg(APP695)3Dbo allele
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
003375   C3B6-Tg(APP695)3Dbo/Mmjax
View Strains carrying   Tg(APP695)3Dbo     (2 strains)

View Strains carrying other alleles of APP695     (8 strains)

View Strains carrying other alleles of PSEN1     (6 strains)

Strains carrying other alleles of Prn
005864   B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
004462   B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
003627   B6C3-Tg(HD82Gln)81Gschi/J
View Strains carrying other alleles of Prn     (3 strains)

Strains carrying other alleles of Prnp
012938   129-Prnptm2Edin/J
016925   129;B6-Del(10Grin3b-Tmem259)1Zang Tg(Prnp-C19ORF6,-GFP)6Zhang/J
003960   129S6-Tg(Prnp-GFP/cre)1Blw/J
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
006823   B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J
010700   B6.Cg-Tg(Prnp-TARDBP*A315T)95Balo/J
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
004479   B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J
018917   B6;SJL-Tg(Prnp-CCS)17Jlel/J
008216   B6CBA(FVB)-Tg(Prnp-TBP*)71-16Xjl/J
008075   B6CBA-Tg(Prnp-TBP*)105Xjl/J
008083   B6CBA-Tg(Prnp-TBP*)13Xjl/J
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
017907   B6N.Cg-Tg(Prnp-TARDBP)96Dwc/J
017933   B6N.Cg-Tg(Prnp-TARDBP*Q331K)103Dwc/J
017930   B6N.Cg-Tg(Prnp-TARDBP*Q331K)109Dwc/J
025402   B6SJL-Tg(Prnp-Immt/SOD1)1Gmnf/J
025403   B6SJL-Tg(Prnp-Immt/SOD1*G93A)7Gmnf/J
016201   B6SJL-Tg(Prnp-TARDBP)4Jlel/J
016203   B6SJL-Tg(Prnp-TARDBP*A315T)23Jlel/J
016608   C57BL/6-Tg(Prnp-TARDBP)3cPtrc/J
017604   C57BL/6-Tg(Prnp-TARDBP*M337V)4Ptrc/J
019517   FVB-Tg(Prnp-HSPB1)1Kolb/J
019482   FVB-Tg(Prnp-HSPB1*R136W)1Kolb/J
018122   FVB.129S7(B6)-Prnptm1Cwe/J
017678   FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J
017744   FVB;129-Tg(Prnp-SNCA*A53T)AAub/J
017916   STOCK Tg(Prnp-FUS)WT3Cshw/J
016144   STOCK Tg(Prnp-TARDBP)4Jlel/J
016143   STOCK Tg(Prnp-TARDBP*A315T)23Jlel/J
008212   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(Prnp-SMN)92Ahmb/J
View Strains carrying other alleles of Prnp     (39 strains)

Additional Web Information

Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Alzheimer Disease 3
Alzheimer Disease 4
Alzheimer Disease; AD
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
Acne Inversa, Familial, 3; ACNINV3   (PSEN1)
Cardiomyopathy, Dilated, 1u; CMD1U   (PSEN1)
Frontotemporal Dementia; FTD   (PSEN1)
Pick Disease of Brain   (PSEN1)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Tg(APP695)3Dbo/0 Tg(PSEN1)5Dbo/0

        involves: C3H/HeJ * C57BL/6J
  • nervous system phenotype
  • *normal* nervous system phenotype
    • no differences in neuron number in cingulate cortex relative to wild-type   (MGI Ref ID J:100961)
    • abnormal neuron morphology
      • dystrophic neuritis associated with reactive gliosis in cortex and hippocampus   (MGI Ref ID J:43788)
    • abnormal neuron physiology
      • neurons in cingulate cortex display 3-fold elevation in phosphorylated tumor suppressor protein (pRb) and activated caspase-3 relative to wild-type neurons   (MGI Ref ID J:100961)
    • amyloid beta deposits
      • amyloid beta deposits found in cortex and hippocampus tissue from 9 and 12 month old mice and increase in number between 10 ans 12 months of age   (MGI Ref ID J:43788)
      • amyloid beta peptides AB1-40 and AB1-42 are codeposited   (MGI Ref ID J:43788)
      • ratio of amyloid beta peptide 40:42 is 1.75:1   (MGI Ref ID J:87691)
      • exhibits a 50% increase in amyloid beta peptide 42   (MGI Ref ID J:87691)
      • immunoreactive amyloid beta deposits are observed in the cingulate cortex in 12 month-old double transgenic mice; deposits are most evident in gray matter of cingulate and enthorhinal cortex, and to lesser extent in non-neuronal layers of the hippocampal formation   (MGI Ref ID J:100961)
    • astrocytosis
      • associated with dystropic neuritis in cortex and hippocampus   (MGI Ref ID J:43788)
  • homeostasis/metabolism phenotype
  • amyloid beta deposits
    • amyloid beta deposits found in cortex and hippocampus tissue from 9 and 12 month old mice and increase in number between 10 ans 12 months of age   (MGI Ref ID J:43788)
    • amyloid beta peptides AB1-40 and AB1-42 are codeposited   (MGI Ref ID J:43788)
    • ratio of amyloid beta peptide 40:42 is 1.75:1   (MGI Ref ID J:87691)
    • exhibits a 50% increase in amyloid beta peptide 42   (MGI Ref ID J:87691)
    • immunoreactive amyloid beta deposits are observed in the cingulate cortex in 12 month-old double transgenic mice; deposits are most evident in gray matter of cingulate and enthorhinal cortex, and to lesser extent in non-neuronal layers of the hippocampal formation   (MGI Ref ID J:100961)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(APP695)3Dbo/0 Tg(PSEN1)5Dbo/0

        B6.Cg-Tg(APP695)3Dbo Tg(PSEN1)5Dbo
  • nervous system phenotype
  • amyloid beta deposits
    • at 12 and 17 months of age, females have significantly more plaques in the hippocampus compared to males; plaque load increases dramatically with age in mice, particularly in females   (MGI Ref ID J:100956)
  • behavior/neurological phenotype
  • abnormal discrimination learning
    • escape latencies across trial blocks in left-right discrimination learning are elevated and decrease little in comparison to decreased escape latencies exhibited in controls   (MGI Ref ID J:142183)
    • required higher trials to reach criterion and committed more errors in comparison to controls   (MGI Ref ID J:142183)
  • abnormal nest building behavior
    • poor nest building ability in comparison to controls   (MGI Ref ID J:142183)
  • abnormal touch/ nociception
    • increased irritability in response to touch escape test as compared to control   (MGI Ref ID J:142183)
  • behavioral despair
    • increased duration of immobility in Porsolt forced swim test   (MGI Ref ID J:142183)
  • impaired passive avoidance behavior
    • poor retention latency exhibited in light-dark step through box   (MGI Ref ID J:142183)
  • integument phenotype
  • abnormal touch/ nociception
    • increased irritability in response to touch escape test as compared to control   (MGI Ref ID J:142183)
  • homeostasis/metabolism phenotype
  • amyloid beta deposits
    • at 12 and 17 months of age, females have significantly more plaques in the hippocampus compared to males; plaque load increases dramatically with age in mice, particularly in females   (MGI Ref ID J:100956)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Alzheimer's Disease
      APP and PSEN1 mutants
      Presenilin mutants
      strains expressing mutant APP

Tg(APP695)3Dbo related

Neurobiology Research
Alzheimer's Disease
Neurodegeneration

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(APP695)3Dbo
Allele Name transgene insertion 3, David R Borchelt
Allele Type Transgenic (Inserted expressed sequence)
Common Name(s) APP695; APP695swe; APPswe; Mo/HuAPPswe; line C3-3;
Mutation Made ByDr. David Borchelt,   University of Florida
Strain of Origin(C57BL/6J x C3H/HeJ)F2
Expressed Gene APP695, amyloid beta (A4) precursor protein (chimeric), mouse/human chimera
Promoter Prn, prion protein gene complex, mouse, laboratory
General Note Three transgenic lines were generated and designated by the authors lines Q2-2, E1-2 (Tg(Prnp-App/APPswe)E1-2Dbo) and C3-3.

This line was generated from founder number C3-3.

Transgenic mice develop amyloid deposits in brain tissue by 18-20 months of age.

Transgenic mice that are also transgenic for Tg(PSEN1)5Dboexpress both human presenilin 1 (A246E variant) and a chimeric amyloid precursor protein (APPSwe) under direction of the mouse prion protein promoter. Elevated levels of the AB1-42(43) peptide are detected in brain homogenates. By nine months of age, histological examination of brain tissue from these mice reveals numerous amyloid deposits resembling those observed in the brains of patients with Alzheimer's disease (AD). The number of amyloid deposits increases dramatically between the ages of 10 and 12 months.

Molecular Note The transgene is composed of a cDNA encoding a chimeric APP protein regulated by the mouse prion promoter. The chimeric APP molecule was created by replacing sequences encoding the Abeta domain of a 695 amino acid isoform of the murine sequence with the cognate sequences of the human gene (mutations K595N, M596L). The human mutations are found in familial Alzheimer's disease. Transgene expression was observed in the brain and heart by Western blot analysis using a monoclonal antibody recognizing the human Abeta region. [MGI Ref ID J:80782]
 
 
 
Allele Symbol Tg(PSEN1)5Dbo
Allele Name transgene insertion 5, David R Borchelt
Allele Type Transgenic (Humanized sequence, Inserted expressed sequence)
Common Name(s) APP/PS1; Hu PS1-A246E; PS1 A246E; PS1-A246E; PS1/A246E; PS1A246E; Tg(PSEN1*A246E)5Dbo;
Mutation Made ByDr. David Borchelt,   University of Florida
Expressed Gene PSEN1, presenilin 1, human
Promoter Prnp, prion protein, mouse, laboratory
General Note This line was generated from founder number N-5.

Transgenic mice that are also transgenic for Tg(APP695)3Dboexpress both human presenilin 1 (A246E variant) and a chimeric amyloid precursor protein (APPSwe) under direction of the mouse prion protein promoter. Elevated levels of the AB1-42(43) peptide are detected in brain homogenates. By nine months of age, histological examination of brain tissue from these mice reveals numerousamyloid deposits resembling those observed in the brains of patients with Alzheimer's disease (AD). The number of amyloid deposits increases dramatically between the ages of 10 and 12 months.

Molecular Note The transgene consists of a mouse prion promoter and a cDNA encoding human presenilin 1 bearing the A246E substitution found in familial Alzheimer's disease (FAD). Transgene expression was verified by Northern and Western blot analysis of brain extracts derived from transgenic animals. [MGI Ref ID J:80882]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(PSEN1), Melt Curve Analysis
Tg(PSEN1), Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Borchelt DR; Ratovitski T; van Lare J; Lee MK; Gonzales V; Jenkins NA; Copeland NG; Price DL; Sisodia SS. 1997. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19(4):939-45. [PubMed: 9354339]  [MGI Ref ID J:43788]

Additional References

Borchelt DR; Davis J; Fischer M; Lee MK; Slunt HH; Ratovitsky T; Regard J; Copeland NG; Jenkins NA; Sisodia SS; Price DL. 1996. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13(6):159-63. [PubMed: 9117892]  [MGI Ref ID J:80782]

Borchelt DR; Thinakaran G; Eckman CB; Lee MK; Davenport F; Ratovitsky T; Prada CM; Kim G; Seekins S; Yager D; Slunt HH; Wang R; Seeger M; Levey AI; Gandy SE; Copeland NG; Jenkins NA; Price DL; Younkin SG; Sisodia SS. 1996. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17(5):1005-13. [PubMed: 8938131]  [MGI Ref ID J:80882]

Filali M; Lalonde R; Rivest S. 2008. Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 8(2):143-8. [PubMed: 19077180]  [MGI Ref ID J:142183]

Tg(APP695)3Dbo related

Bailey AR; Hou H; Obregon DF; Tian J; Zhu Y; Zou Q; Nikolic WV; Bengtson M; Mori T; Murphy T; Tan J. 2012. Aberrant T-lymphocyte development and function in mice overexpressing human soluble amyloid precursor protein-alpha: implications for autism. FASEB J 26(3):1040-51. [PubMed: 22085641]  [MGI Ref ID J:182808]

Boissonneault V; Plante I; Rivest S; Provost P. 2009. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem 284(4):1971-81. [PubMed: 18986979]  [MGI Ref ID J:146980]

Borchelt DR; Davis J; Fischer M; Lee MK; Slunt HH; Ratovitsky T; Regard J; Copeland NG; Jenkins NA; Sisodia SS; Price DL. 1996. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal 13(6):159-63. [PubMed: 9117892]  [MGI Ref ID J:80782]

Borchelt DR; Thinakaran G; Eckman CB; Lee MK; Davenport F; Ratovitsky T; Prada CM; Kim G; Seekins S; Yager D; Slunt HH; Wang R; Seeger M; Levey AI; Gandy SE; Copeland NG; Jenkins NA; Price DL; Younkin SG; Sisodia SS. 1996. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17(5):1005-13. [PubMed: 8938131]  [MGI Ref ID J:80882]

Cai D; Zhong M; Wang R; Netzer WJ; Shields D; Zheng H; Sisodia SS; Foster DA; Gorelick FS; Xu H; Greengard P. 2006. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A 103(6):1936-40. [PubMed: 16449385]  [MGI Ref ID J:106075]

Cai Y; Xue ZQ; Zhang XM; Li MB; Wang H; Luo XG; Cai H; Yan XX. 2012. An age-related axon terminal pathology around the first olfactory relay that involves amyloidogenic protein overexpression without plaque formation. Neuroscience 215:160-73. [PubMed: 22542680]  [MGI Ref ID J:192436]

Dodson SE; Andersen OM; Karmali V; Fritz JJ; Cheng D; Peng J; Levey AI; Willnow TE; Lah JJ. 2008. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J Neurosci 28(48):12877-86. [PubMed: 19036982]  [MGI Ref ID J:142501]

Dolev I; Fogel H; Milshtein H; Berdichevsky Y; Lipstein N; Brose N; Gazit N; Slutsky I. 2013. Spike bursts increase amyloid-beta 40/42 ratio by inducing a presenilin-1 conformational change. Nat Neurosci 16(5):587-95. [PubMed: 23563578]  [MGI Ref ID J:197603]

El-Amouri SS; Zhu H; Yu J; Marr R; Verma IM; Kindy MS. 2008. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 172(5):1342-54. [PubMed: 18403590]  [MGI Ref ID J:134308]

Filali M; Lalonde R. 2009. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292:93-9. [PubMed: 19643098]  [MGI Ref ID J:157207]

Filali M; Lalonde R; Rivest S. 2008. Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 8(2):143-8. [PubMed: 19077180]  [MGI Ref ID J:142183]

Filali M; Lalonde R; Rivest S. 2011. Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology 60(6):930-6. [PubMed: 21281652]  [MGI Ref ID J:178504]

Garcia-Alloza M; Dodwell SA; Meyer-Luehmann M; Hyman BT; Bacskai BJ. 2006. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J Neuropathol Exp Neurol 65(11):1082-9. [PubMed: 17086105]  [MGI Ref ID J:120918]

Gureviciene I; Ikonen S; Gurevicius K; Sarkaki A; van Groen T; Pussinen R; Ylinen A; Tanila H. 2004. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. Neurobiol Dis 15(2):188-95. [PubMed: 15006688]  [MGI Ref ID J:128772]

Helft J; Manicassamy B; Guermonprez P; Hashimoto D; Silvin A; Agudo J; Brown BD; Schmolke M; Miller JC; Leboeuf M; Murphy KM; Garcia-Sastre A; Merad M. 2012. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J Clin Invest 122(11):4037-47. [PubMed: 23041628]  [MGI Ref ID J:193561]

Huang HJ; Liang KC; Ke HC; Chang YY; Hsieh-Li HM. 2011. Long-term social isolation exacerbates the impairment of spatial working memory in APP/PS1 transgenic mice. Brain Res 1371:150-60. [PubMed: 21114967]  [MGI Ref ID J:170247]

Iivonen H; Nurminen L; Harri M; Tanila H; Puolivali J. 2003. Hypothermia in mice tested in Morris water maze. Behav Brain Res 141(2):207-13. [PubMed: 12742257]  [MGI Ref ID J:130974]

Jankowsky JL; Fadale DJ; Anderson J; Xu GM; Gonzales V; Jenkins NA; Copeland NG; Lee MK; Younkin LH; Wagner SL; Younkin SG; Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2):159-70. [PubMed: 14645205]  [MGI Ref ID J:87691]

Jankowsky JL; Melnikova T; Fadale DJ; Xu GM; Slunt HH; Gonzales V; Younkin LH; Younkin SG; Borchelt DR; Savonenko AV. 2005. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 25(21):5217-24. [PubMed: 15917461]  [MGI Ref ID J:98541]

Jankowsky JL; Slunt HH; Gonzales V; Jenkins NA; Copeland NG; Borchelt DR. 2004. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25(7):885-92. [PubMed: 15212842]  [MGI Ref ID J:102351]

Kalesnykas G; Roschier U; Puolivali J; Wang J; Miettinen R. 2005. The effect of aging on the subcellular distribution of estrogen receptor-alpha in the cholinergic neurons of transgenic and wild-type mice. Eur J Neurosci 21(5):1437-42. [PubMed: 15813954]  [MGI Ref ID J:101077]

Kanekiyo T; Cirrito JR; Liu CC; Shinohara M; Li J; Schuler DR; Shinohara M; Holtzman DM; Bu G. 2013. Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci 33(49):19276-83. [PubMed: 24305823]  [MGI Ref ID J:204149]

Kanekiyo T; Liu CC; Shinohara M; Li J; Bu G. 2012. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-beta. J Neurosci 32(46):16458-65. [PubMed: 23152628]  [MGI Ref ID J:192453]

Ke HC; Huang HJ; Liang KC; Hsieh-Li HM. 2011. Selective improvement of cognitive function in adult and aged APP/PS1 transgenic mice by continuous non-shock treadmill exercise. Brain Res 1403:1-11. [PubMed: 21689809]  [MGI Ref ID J:174067]

Khan UA; Liu L; Provenzano FA; Berman DE; Profaci CP; Sloan R; Mayeux R; Duff KE; Small SA. 2014. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 17(2):304-11. [PubMed: 24362760]  [MGI Ref ID J:208008]

Laird FM; Cai H; Savonenko AV; Farah MH; He K; Melnikova T; Wen H; Chiang HC; Xu G; Koliatsos VE; Borchelt DR; Price DL; Lee HK; Wong PC. 2005. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25(50):11693-709. [PubMed: 16354928]  [MGI Ref ID J:123534]

Lazarov O; Morfini GA; Pigino G; Gadadhar A; Chen X; Robinson J; Ho H; Brady ST; Sisodia SS. 2007. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27(26):7011-20. [PubMed: 17596450]  [MGI Ref ID J:122975]

Lee GD; Aruna JH; Barrett PM; Lei DL; Ingram DK; Mouton PR. 2005. Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease. Brain Res Bull 65(4):317-22. [PubMed: 15811597]  [MGI Ref ID J:135436]

Lesuisse C; Xu G; Anderson J; Wong M; Jankowsky J; Holtz G; Gonzalez V; Wong PC; Price DL; Tang F; Wagner S; Borchelt DR. 2001. Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum Mol Genet 10(22):2525-37. [PubMed: 11709540]  [MGI Ref ID J:72987]

Li G; Zou L; Jack CR Jr; Yang Y; Yang ES. 2007. Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein. Neurobiol Aging 28(6):877-82. [PubMed: 16806588]  [MGI Ref ID J:121939]

Li L; Zhang X; Yang D; Luo G; Chen S; Le W. 2009. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 30(7):1091-8. [PubMed: 18063223]  [MGI Ref ID J:152965]

Liang C; Zhu H; Xu Y; Huang L; Ma C; Deng W; Liu Y; Qin C. 2012. MicroRNA-153 negatively regulates the expression of amyloid precursor protein and amyloid precursor-like protein 2. Brain Res 1455:103-13. [PubMed: 22510281]  [MGI Ref ID J:186457]

Liu L; Ikonen S; Heikkinen T; Heikkila M; Puolivali J; van Groen T; Tanila H. 2002. Effects of fimbria-fornix lesion and amyloid pathology on spatial learning and memory in transgenic APP+PS1 mice. Behav Brain Res 134(1-2):433-45. [PubMed: 12191831]  [MGI Ref ID J:129807]

Liu L; Tapiola T; Herukka SK; Heikkila M; Tanila H. 2003. Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. Neuroreport 14(1):163-6. [PubMed: 12544850]  [MGI Ref ID J:89843]

Liu Y; Yoo MJ; Savonenko A; Stirling W; Price DL; Borchelt DR; Mamounas L; Lyons WE; Blue ME; Lee MK. 2008. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28(51):13805-14. [PubMed: 19091971]  [MGI Ref ID J:143521]

Lopez JR; Lyckman A; Oddo S; Laferla FM; Querfurth HW; Shtifman A. 2008. Increased intraneuronal resting [Ca2+] in adult Alzheimer's disease mice. J Neurochem 105(1):262-71. [PubMed: 18021291]  [MGI Ref ID J:141555]

Manczak M; Reddy PH. 2012. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21(11):2538-47. [PubMed: 22367970]  [MGI Ref ID J:183771]

Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI. 2006. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 141(3):1149-62. [PubMed: 16753269]  [MGI Ref ID J:111748]

Montgomery KS; Simmons RK; Edwards G 3rd; Nicolle MM; Gluck MA; Myers CE; Bizon JL. 2011. Novel age-dependent learning deficits in a mouse model of Alzheimer's disease: Implications for translational research. Neurobiol Aging 32(7):1273-85. [PubMed: 19720431]  [MGI Ref ID J:173732]

Naert G; Rivest S. 2011. CC Chemokine Receptor 2 Deficiency Aggravates Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. J Neurosci 31(16):6208-20. [PubMed: 21508244]  [MGI Ref ID J:171601]

Nikolajsen GN; Jensen MS; West MJ. 2011. Cholinergic axon length reduced by 300 meters in the brain of an Alzheimer mouse model. Neurobiol Aging 32(11):1927-31. [PubMed: 21752495]  [MGI Ref ID J:176689]

Oh ES; Savonenko AV; King JF; Fangmark Tucker SM; Rudow GL; Xu G; Borchelt DR; Troncoso JC. 2009. Amyloid precursor protein increases cortical neuron size in transgenic mice. Neurobiol Aging 30(8):1238-44. [PubMed: 18304698]  [MGI Ref ID J:152955]

Ojala J; Alafuzoff I; Herukka SK; van Groen T; Tanila H; Pirttila T. 2009. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging 30(2):198-209. [PubMed: 17658666]  [MGI Ref ID J:145816]

Paban V; Manrique C; Filali M; Maunoir-Regimbal S; Fauvelle F; Alescio-Lautier B. 2014. Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. Neuropharmacology 76 Pt A:68-79. [PubMed: 23891615]  [MGI Ref ID J:214171]

Perez SE; Dar S; Ikonomovic MD; DeKosky ST; Mufson EJ. 2007. Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol Dis 28(1):3-15. [PubMed: 17662610]  [MGI Ref ID J:134818]

Perez SE; Lazarov O; Koprich JB; Chen EY; Rodriguez-Menendez V; Lipton JW; Sisodia SS; Mufson EJ. 2005. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci 25(44):10220-9. [PubMed: 16267229]  [MGI Ref ID J:102362]

Perez SE; Lumayag S; Kovacs B; Mufson EJ; Xu S. 2008. {beta}-Amyloid Deposition and Functional Impairment in the Retina of the APPswe/PS1{Delta}E9 Transgenic Mouse Model of Alzheimer's Disease. Invest Ophthalmol Vis Sci 50(2):793-800. [PubMed: 18791173]  [MGI Ref ID J:139070]

Pimentel-Coelho PM; Michaud JP; Rivest S. 2013. Effects of mild chronic cerebral hypoperfusion and early amyloid pathology on spatial learning and the cellular innate immune response in mice. Neurobiol Aging 34(3):679-93. [PubMed: 22819135]  [MGI Ref ID J:194432]

Pistell PJ; Zhu M; Ingram DK. 2008. Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience 152(3):594-600. [PubMed: 18304749]  [MGI Ref ID J:135640]

Popovic M; Caballero-Bleda M; Kadish I; Van Groen T. 2008. Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice. Neuroscience 155(1):182-91. [PubMed: 18583063]  [MGI Ref ID J:140778]

Richard KL; Filali M; Prefontaine P; Rivest S. 2008. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 28(22):5784-93. [PubMed: 18509040]  [MGI Ref ID J:136387]

Ricoy UM; Mao P; Manczak M; Reddy PH; Frerking ME. 2011. A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics. Neurosci Lett 500(3):212-5. [PubMed: 21741442]  [MGI Ref ID J:174545]

Rodriguez JJ; Olabarria M; Chvatal A; Verkhratsky A. 2009. Astroglia in dementia and Alzheimer's disease. Cell Death Differ 16(3):378-85. [PubMed: 19057621]  [MGI Ref ID J:158080]

Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR. 2005. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18(3):602-17. [PubMed: 15755686]  [MGI Ref ID J:104236]

Savonenko AV; Xu GM; Price DL; Borchelt DR; Markowska AL. 2003. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol Dis 12(3):194-211. [PubMed: 12742740]  [MGI Ref ID J:109847]

Simard AR; Soulet D; Gowing G; Julien JP; Rivest S. 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49(4):489-502. [PubMed: 16476660]  [MGI Ref ID J:107605]

Simpson RJ. 1992. Effect of hypoxic exposure on iron absorption in heterozygous hypotransferrinaemic mice. Ann Hematol 65(6):260-4. [PubMed: 1457587]  [MGI Ref ID J:12201]

Soderman A; Mikkelsen JD; West MJ; Christensen DZ; Jensen MS. 2011. Activation of nicotinic alpha(7) acetylcholine receptor enhances long term potentation in wild type mice but not in APP(swe)/PS1DeltaE9 mice. Neurosci Lett 487(3):325-9. [PubMed: 20974225]  [MGI Ref ID J:168638]

Soderman A; Thomsen MS; Hansen HH; Nielsen EO; Jensen MS; West MJ; Mikkelsen JD. 2008. The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. Brain Res 1227:240-7. [PubMed: 18619425]  [MGI Ref ID J:139987]

Son SM; Jung ES; Shin HJ; Byun J; Mook-Jung I. 2012. Abeta-induced formation of autophagosomes is mediated by RAGE-CaMKKbeta-AMPK signaling. Neurobiol Aging 33(5):1006.e11-23. [PubMed: 22048125]  [MGI Ref ID J:188183]

Stokin GB; Lillo C; Falzone TL; Brusch RG; Rockenstein E; Mount SL; Raman R; Davies P; Masliah E; Williams DS; Goldstein LS. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307(5713):1282-8. [PubMed: 15731448]  [MGI Ref ID J:96346]

Sun X; Wu Y; Gu M; Zhang Y. 2014. miR-342-5p decreases ankyrin G levels in Alzheimer's disease transgenic mouse models. Cell Rep 6(2):264-70. [PubMed: 24440716]  [MGI Ref ID J:208793]

Szapacs ME; Numis AL; Andrews AM. 2004. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol Dis 16(3):572-80. [PubMed: 15262269]  [MGI Ref ID J:131666]

Tang J; Song M; Wang Y; Fan X; Xu H; Bai Y. 2009. Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun 385(3):341-5. [PubMed: 19463786]  [MGI Ref ID J:150675]

Turdi S; Guo R; Huff AF; Wolf EM; Culver B; Ren J. 2009. Cardiomyocyte contractile dysfunction in the APPswe/PS1dE9 mouse model of Alzheimer's disease. PLoS One 4(6):e6033. [PubMed: 19551139]  [MGI Ref ID J:150191]

Veeraraghavalu K; Zhang C; Zhang X; Tanzi RE; Sisodia SS. 2014. Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of beta-amyloid by cells other than excitatory neurons. J Neurosci 34(10):3668-73. [PubMed: 24599465]  [MGI Ref ID J:209619]

Vepsalainen S; Hiltunen M; Helisalmi S; Wang J; van Groen T; Tanila H; Soininen H. 2008. Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett 438(2):216-20. [PubMed: 18455870]  [MGI Ref ID J:136710]

Verret L; Jankowsky JL; Xu GM; Borchelt DR; Rampon C. 2007. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci 27(25):6771-80. [PubMed: 17581964]  [MGI Ref ID J:122001]

Wang CM; Devries S; Camboni M; Glass M; Martin PT. 2010. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis 39(3):409-22. [PubMed: 20493257]  [MGI Ref ID J:163033]

Wang J; Ikonen S; Gurevicius K; Van Groen T; Tanila H. 2003. Altered auditory-evoked potentials in mice carrying mutated human amyloid precursor protein and presenilin-1 transgenes. Neuroscience 116(2):511-7. [PubMed: 12559106]  [MGI Ref ID J:128594]

Wang J; Ikonen S; Gurevicius K; van Groen T; Tanila H. 2002. Alteration of cortical EEG in mice carrying mutated human APP transgene. Brain Res 943(2):181-90. [PubMed: 12101040]  [MGI Ref ID J:78111]

Wang J; Tanila H; Puolivali J; Kadish I; van Groen T. 2003. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 14(3):318-27. [PubMed: 14678749]  [MGI Ref ID J:100956]

Wang X; Liu P; Zhu H; Xu Y; Ma C; Dai X; Huang L; Liu Y; Zhang L; Qin C. 2009. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 80(4-5):268-73. [PubMed: 19683563]  [MGI Ref ID J:186827]

Wasik U; Schneider G; Mietelska-Porowska A; Mazurkiewicz M; Fabczak H; Weis S; Zabke C; Harrington CR; Filipek A; Niewiadomska G. 2013. Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function. Neurobiol Aging 34(5):1380-8. [PubMed: 23260124]  [MGI Ref ID J:203376]

Xiang Z; Ho L; Valdellon J; Borchelt D; Kelley K; Spielman L; Aisen PS; Pasinetti GM. 2002. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 23(3):327-34. [PubMed: 11959394]  [MGI Ref ID J:100961]

Xie H; Hou S; Jiang J; Sekutowicz M; Kelly J; Bacskai BJ. 2013. Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci U S A 110(19):7904-9. [PubMed: 23610434]  [MGI Ref ID J:197345]

Yan P; Bero AW; Cirrito JR; Xiao Q; Hu X; Wang Y; Gonzales E; Holtzman DM; Lee JM. 2009. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 29(34):10706-14. [PubMed: 19710322]  [MGI Ref ID J:152312]

Yang Y; Cudaback E; Jorstad NL; Hemingway JF; Hagan CE; Melief EJ; Li X; Yoo T; Khademi SB; Montine KS; Montine TJ; Keene CD. 2013. APOE3, but Not APOE4, Bone Marrow Transplantation Mitigates Behavioral and Pathological Changes in a Mouse Model of Alzheimer Disease. Am J Pathol 183(3):905-17. [PubMed: 23831297]  [MGI Ref ID J:200093]

Yang Y; Shiao C; Hemingway JF; Jorstad NL; Shalloway BR; Chang R; Keene CD. 2013. Suppressed retinal degeneration in aged wild type and APPswe/PS1DeltaE9 mice by bone marrow transplantation. PLoS One 8(6):e64246. [PubMed: 23750207]  [MGI Ref ID J:204261]

Zhang J; Guo J; Zhao X; Chen Z; Wang G; Liu A; Wang Q; Zhou W; Xu Y; Wang C. 2013. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 250:230-7. [PubMed: 23685322]  [MGI Ref ID J:202125]

Zhang X; Li L; Zhang X; Xie W; Li L; Yang D; Heng X; Du Y; Doody RS; Le W. 2013. Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging 34(3):663-78. [PubMed: 22795785]  [MGI Ref ID J:194433]

Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX. 2009. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 30(12):2271-83. [PubMed: 20092570]  [MGI Ref ID J:157228]

Zhang Y; Zhou B; Zhang F; Wu J; Hu Y; Liu Y; Zhai Q. 2012. Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61(6):1434-43. [PubMed: 22522613]  [MGI Ref ID J:196823]

Zhou XW; Gustafsson JA; Tanila H; Bjorkdahl C; Liu R; Winblad B; Pei JJ. 2008. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis 31(3):386-94. [PubMed: 18586097]  [MGI Ref ID J:138611]

van Groen T; Liu L; Ikonen S; Kadish I. 2003. Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. Neuroscience 119(4):1185-97. [PubMed: 12831872]  [MGI Ref ID J:100957]

Tg(PSEN1)5Dbo related

Boissonneault V; Plante I; Rivest S; Provost P. 2009. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem 284(4):1971-81. [PubMed: 18986979]  [MGI Ref ID J:146980]

Borchelt DR; Thinakaran G; Eckman CB; Lee MK; Davenport F; Ratovitsky T; Prada CM; Kim G; Seekins S; Yager D; Slunt HH; Wang R; Seeger M; Levey AI; Gandy SE; Copeland NG; Jenkins NA; Price DL; Younkin SG; Sisodia SS. 1996. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17(5):1005-13. [PubMed: 8938131]  [MGI Ref ID J:80882]

Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA. 2013. IFN-gamma Production by Amyloid beta-Specific Th1 Cells Promotes Microglial Activation and Increases Plaque Burden in a Mouse Model of Alzheimer's Disease. J Immunol 190(5):2241-51. [PubMed: 23365075]  [MGI Ref ID J:193461]

Filali M; Lalonde R. 2009. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292:93-9. [PubMed: 19643098]  [MGI Ref ID J:157207]

Filali M; Lalonde R; Rivest S. 2008. Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 8(2):143-8. [PubMed: 19077180]  [MGI Ref ID J:142183]

Filali M; Lalonde R; Rivest S. 2011. Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology 60(6):930-6. [PubMed: 21281652]  [MGI Ref ID J:178504]

Gureviciene I; Ikonen S; Gurevicius K; Sarkaki A; van Groen T; Pussinen R; Ylinen A; Tanila H. 2004. Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. Neurobiol Dis 15(2):188-95. [PubMed: 15006688]  [MGI Ref ID J:128772]

Haughey NJ; Nath A; Chan SL; Borchard AC; Rao MS; Mattson MP. 2002. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 83(6):1509-24. [PubMed: 12472904]  [MGI Ref ID J:80820]

Huang HJ; Liang KC; Ke HC; Chang YY; Hsieh-Li HM. 2011. Long-term social isolation exacerbates the impairment of spatial working memory in APP/PS1 transgenic mice. Brain Res 1371:150-60. [PubMed: 21114967]  [MGI Ref ID J:170247]

Iivonen H; Nurminen L; Harri M; Tanila H; Puolivali J. 2003. Hypothermia in mice tested in Morris water maze. Behav Brain Res 141(2):207-13. [PubMed: 12742257]  [MGI Ref ID J:130974]

Jankowsky JL; Fadale DJ; Anderson J; Xu GM; Gonzales V; Jenkins NA; Copeland NG; Lee MK; Younkin LH; Wagner SL; Younkin SG; Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2):159-70. [PubMed: 14645205]  [MGI Ref ID J:87691]

Jankowsky JL; Melnikova T; Fadale DJ; Xu GM; Slunt HH; Gonzales V; Younkin LH; Younkin SG; Borchelt DR; Savonenko AV. 2005. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 25(21):5217-24. [PubMed: 15917461]  [MGI Ref ID J:98541]

Kalesnykas G; Roschier U; Puolivali J; Wang J; Miettinen R. 2005. The effect of aging on the subcellular distribution of estrogen receptor-alpha in the cholinergic neurons of transgenic and wild-type mice. Eur J Neurosci 21(5):1437-42. [PubMed: 15813954]  [MGI Ref ID J:101077]

Kanekiyo T; Liu CC; Shinohara M; Li J; Bu G. 2012. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-beta. J Neurosci 32(46):16458-65. [PubMed: 23152628]  [MGI Ref ID J:192453]

Ke HC; Huang HJ; Liang KC; Hsieh-Li HM. 2011. Selective improvement of cognitive function in adult and aged APP/PS1 transgenic mice by continuous non-shock treadmill exercise. Brain Res 1403:1-11. [PubMed: 21689809]  [MGI Ref ID J:174067]

Li L; Zhang X; Yang D; Luo G; Chen S; Le W. 2009. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging 30(7):1091-8. [PubMed: 18063223]  [MGI Ref ID J:152965]

Liang C; Zhu H; Xu Y; Huang L; Ma C; Deng W; Liu Y; Qin C. 2012. MicroRNA-153 negatively regulates the expression of amyloid precursor protein and amyloid precursor-like protein 2. Brain Res 1455:103-13. [PubMed: 22510281]  [MGI Ref ID J:186457]

Liu L; Ikonen S; Heikkinen T; Heikkila M; Puolivali J; van Groen T; Tanila H. 2002. Effects of fimbria-fornix lesion and amyloid pathology on spatial learning and memory in transgenic APP+PS1 mice. Behav Brain Res 134(1-2):433-45. [PubMed: 12191831]  [MGI Ref ID J:129807]

Liu L; Tapiola T; Herukka SK; Heikkila M; Tanila H. 2003. Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. Neuroreport 14(1):163-6. [PubMed: 12544850]  [MGI Ref ID J:89843]

Malm TM; Magga J; Kuh GF; Vatanen T; Koistinaho M; Koistinaho J. 2008. Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. Glia 56(16):1767-79. [PubMed: 18649403]  [MGI Ref ID J:156257]

Manczak M; Reddy PH. 2012. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21(11):2538-47. [PubMed: 22367970]  [MGI Ref ID J:183771]

Manczak M; Reddy PH. 2012. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 21(23):5131-46. [PubMed: 22926141]  [MGI Ref ID J:188922]

Mirnics ZK; Yan C; Portugal C; Kim TW; Saragovi HU; Sisodia SS; Mirnics K; Schor NF. 2005. P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiol Dis 20(3):969-85. [PubMed: 16006137]  [MGI Ref ID J:104654]

Naert G; Rivest S. 2011. CC Chemokine Receptor 2 Deficiency Aggravates Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. J Neurosci 31(16):6208-20. [PubMed: 21508244]  [MGI Ref ID J:171601]

Nikolajsen GN; Jensen MS; West MJ. 2011. Cholinergic axon length reduced by 300 meters in the brain of an Alzheimer mouse model. Neurobiol Aging 32(11):1927-31. [PubMed: 21752495]  [MGI Ref ID J:176689]

Ojala J; Alafuzoff I; Herukka SK; van Groen T; Tanila H; Pirttila T. 2009. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging 30(2):198-209. [PubMed: 17658666]  [MGI Ref ID J:145816]

Paban V; Manrique C; Filali M; Maunoir-Regimbal S; Fauvelle F; Alescio-Lautier B. 2014. Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. Neuropharmacology 76 Pt A:68-79. [PubMed: 23891615]  [MGI Ref ID J:214171]

Parent A; Linden DJ; Sisodia SS; Borchelt DR. 1999. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol Dis 6(1):56-62. [PubMed: 10078973]  [MGI Ref ID J:57519]

Pihlaja R; Koistinaho J; Malm T; Sikkila H; Vainio S; Koistinaho M. 2008. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 56(2):154-63. [PubMed: 18004725]  [MGI Ref ID J:156291]

Pimentel-Coelho PM; Michaud JP; Rivest S. 2013. Effects of mild chronic cerebral hypoperfusion and early amyloid pathology on spatial learning and the cellular innate immune response in mice. Neurobiol Aging 34(3):679-93. [PubMed: 22819135]  [MGI Ref ID J:194432]

Platt B; Drever B; Koss D; Stoppelkamp S; Jyoti A; Plano A; Utan A; Merrick G; Ryan D; Melis V; Wan H; Mingarelli M; Porcu E; Scrocchi L; Welch A; Riedel G. 2011. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One 6(11):e27068. [PubMed: 22096518]  [MGI Ref ID J:180977]

Richard KL; Filali M; Prefontaine P; Rivest S. 2008. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 28(22):5784-93. [PubMed: 18509040]  [MGI Ref ID J:136387]

Ricoy UM; Mao P; Manczak M; Reddy PH; Frerking ME. 2011. A transgenic mouse model for Alzheimer's disease has impaired synaptic gain but normal synaptic dynamics. Neurosci Lett 500(3):212-5. [PubMed: 21741442]  [MGI Ref ID J:174545]

Salehi A; Delcroix JD; Belichenko PV; Zhan K; Wu C; Valletta JS; Takimoto-Kimura R; Kleschevnikov AM; Sambamurti K; Chung PP; Xia W; Villar A; Campbell WA; Kulnane LS; Nixon RA; Lamb BT; Epstein CJ; Stokin GB; Goldstein LS; Mobley WC. 2006. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51(1):29-42. [PubMed: 16815330]  [MGI Ref ID J:122937]

Scott L; Feng J; Kiss T; Needle E; Atchison K; Kawabe TT; Milici AJ; Hajos-Korcsok E; Riddell D; Hajos M. 2012. Age-dependent disruption in hippocampal theta oscillation in amyloid-beta overproducing transgenic mice. Neurobiol Aging 33(7):1481.e13-23. [PubMed: 22227005]  [MGI Ref ID J:188311]

Serrano J; Fernandez AP; Martinez-Murillo R; Martinez A. 2010. High sensitivity to carcinogens in the brain of a mouse model of Alzheimer's disease. Oncogene 29(15):2165-71. [PubMed: 20101216]  [MGI Ref ID J:160389]

Simard AR; Soulet D; Gowing G; Julien JP; Rivest S. 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49(4):489-502. [PubMed: 16476660]  [MGI Ref ID J:107605]

Stokin GB; Almenar-Queralt A; Gunawardena S; Rodrigues EM; Falzone T; Kim J; Lillo C; Mount SL; Roberts EA; McGowan E; Williams DS; Goldstein LS. 2008. Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum Mol Genet 17(22):3474-86. [PubMed: 18694898]  [MGI Ref ID J:140396]

Vepsalainen S; Hiltunen M; Helisalmi S; Wang J; van Groen T; Tanila H; Soininen H. 2008. Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett 438(2):216-20. [PubMed: 18455870]  [MGI Ref ID J:136710]

Wang CM; Devries S; Camboni M; Glass M; Martin PT. 2010. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis 39(3):409-22. [PubMed: 20493257]  [MGI Ref ID J:163033]

Wang J; Ikonen S; Gurevicius K; Van Groen T; Tanila H. 2003. Altered auditory-evoked potentials in mice carrying mutated human amyloid precursor protein and presenilin-1 transgenes. Neuroscience 116(2):511-7. [PubMed: 12559106]  [MGI Ref ID J:128594]

Wang J; Ikonen S; Gurevicius K; van Groen T; Tanila H. 2002. Alteration of cortical EEG in mice carrying mutated human APP transgene. Brain Res 943(2):181-90. [PubMed: 12101040]  [MGI Ref ID J:78111]

Wang J; Tanila H; Puolivali J; Kadish I; van Groen T. 2003. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 14(3):318-27. [PubMed: 14678749]  [MGI Ref ID J:100956]

Wasik U; Schneider G; Mietelska-Porowska A; Mazurkiewicz M; Fabczak H; Weis S; Zabke C; Harrington CR; Filipek A; Niewiadomska G. 2013. Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function. Neurobiol Aging 34(5):1380-8. [PubMed: 23260124]  [MGI Ref ID J:203376]

Xiang Z; Ho L; Valdellon J; Borchelt D; Kelley K; Spielman L; Aisen PS; Pasinetti GM. 2002. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 23(3):327-34. [PubMed: 11959394]  [MGI Ref ID J:100961]

Xie H; Hou S; Jiang J; Sekutowicz M; Kelly J; Bacskai BJ. 2013. Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci U S A 110(19):7904-9. [PubMed: 23610434]  [MGI Ref ID J:197345]

Zhang J; Guo J; Zhao X; Chen Z; Wang G; Liu A; Wang Q; Zhou W; Xu Y; Wang C. 2013. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 250:230-7. [PubMed: 23685322]  [MGI Ref ID J:202125]

Zhang X; Li L; Zhang X; Xie W; Li L; Yang D; Heng X; Du Y; Doody RS; Le W. 2013. Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging 34(3):663-78. [PubMed: 22795785]  [MGI Ref ID J:194433]

Zhang Y; Zhou B; Zhang F; Wu J; Hu Y; Liu Y; Zhai Q. 2012. Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61(6):1434-43. [PubMed: 22522613]  [MGI Ref ID J:196823]

Zhou XW; Gustafsson JA; Tanila H; Bjorkdahl C; Liu R; Winblad B; Pei JJ. 2008. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis 31(3):386-94. [PubMed: 18586097]  [MGI Ref ID J:138611]

Zhou XW; Tanila H; Pei JJ. 2008. Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction. FEBS Lett 582(2):159-164. [PubMed: 18068129]  [MGI Ref ID J:130326]

de Diego AM; Lorrio S; Calvo-Gallardo E; Garcia AG. 2012. Smaller quantal size and faster kinetics of single exocytotic events in chromaffin cells from the APP/PS1 mouse model of Alzheimer's disease. Biochem Biophys Res Commun 428(4):482-6. [PubMed: 23123627]  [MGI Ref ID J:191088]

van Groen T; Liu L; Ikonen S; Kadish I. 2003. Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. Neuroscience 119(4):1185-97. [PubMed: 12831872]  [MGI Ref ID J:100957]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryThe strain originated on a mixed B6;C3H background. The investigator maintains the line by mating double transgenics to C3B6F1 mice. The double transgenics are hemizygous; they are not linked (only 1 in 4 pups is a double transgenic); and the integration site is unknown. Reproduction is excellent. TJL maintains this line by mating (APP695/0, +/+) x (+/+, PSEN1/0) (or reciprocal) to distribute mice APP695/+, PSEN1/+. Expected coat colors: agouti, black. TJL will supply 1) hemizygous APP695, wildtype PSEN1; 2) wildtype APP695, hemizygous PSEN1; and 3) double hemizygotes. Breeder pairs will be the hemizygous APP695, wildtype PSEN1 and the wildtype APP695, hemizygous PSEN1 from the colony (and the reciprocal). Control mice can be generated from this breeding pair. Alternatively, investigators can consider B6C3F1/J (Stock 100010).
Mating SystemSee Colony Maintenance under the Health & Care tab         (Female x Male)   01-MAR-06

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   Noncarrier
   100010 B6C3F1/J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Strain(s) not available to companies or for-profit entities.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)